CRISPR Therapeutics AG 8-K

What Happened
CRISPR Therapeutics AG announced results of its June 4, 2026 Annual General Meeting. Shareholders approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan, amendments to the company’s Articles of Association (effective upon Swiss Commercial Register registration on or about June 5, 2026), re-elected 11 board members (including CEO Samarth Kulkarni, Ph.D. as chairman), and re-appointed Ernst & Young AG and Ernst & Young LLP as auditors. The company filed the 8‑K on June 4, 2026 and incorporated the detailed plan and amended charter as exhibits.

Key Details

• 2026 Stock Option & Incentive Plan approved: 42,839,199 FOR, 5,763,564 AGAINST, 152,090 ABSTAIN; broker non-votes: 22,498,855.
• Amended and restated Articles of Association approved; to become effective upon registration in the canton of Zug (subject to Swiss Federal Commercial Authority approval) on or about June 5, 2026.
• Board re-elections: eleven directors re-elected (including Samarth Kulkarni as chairman); vote totals vary by nominee (examples: Kulkarni 47,043,987 FOR; Douglas Treco 44,359,453 FOR).
• Auditors re-elected: Ernst & Young AG (statutory auditor) and Ernst & Young LLP (U.S. independent registered public accounting firm); vote totals: 69,875,653 FOR.
• Capital measures approved: increase to the company’s capital band (69,408,999 FOR) and increase to conditional share capital for bond conversions (47,341,035 FOR).
• Compensation matters: multiple binding and non‑binding votes on board and executive committee compensation passed (examples: board non-performance compensation approved 48,085,285 FOR; non-binding endorsement of 2025 compensation report 39,906,651 FOR).

Why It Matters
These approvals set the framework for future equity awards and capital structure flexibility. The 2026 Plan authorizes a range of equity instruments (options, restricted stock/units, performance awards) using remaining shares from the prior plan and other specified sources, which affects potential dilution and executive/board compensation. Charter amendments and capital increases provide corporate governance and financing flexibility under Swiss law. Re-election of the board and auditors maintains continuity in leadership and financial oversight. Investors should note the vote tallies and large broker non‑votes, which reflect shares not voted at the AGM.